http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3470431-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9f8eff85227fd96744c754de382d6b2
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
filingDate 2013-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d889354ba6d8a00d4a73c6d593bbfaa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0a0303a82a2da885f57d2b5e47987ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_330c1ad919b06ea455bc32d0a17e773f
publicationDate 2019-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3470431-A1
titleOfInvention Bispecific igg antibodies as t cell engagers
abstract The present invention provides human IgG bispecific antibodies, wherein one arm of the antibody binds an epitope on immune effector cells, whilst the other arm targets CLEC12A or a functional equivalent thereof. Pharmaceutical uses of these antibodies against malignancies such as MDS, CML or AML are also provided.
priorityDate 2012-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005000894-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009051974-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010108127-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006171929-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006177451-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011028952-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008027236-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005118635-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009157771-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004009618-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5457035-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009089004-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010151792-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395318
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5366546
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409442
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398631
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397425
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66577526
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395394
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395395
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394880
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6253

Total number of triples: 55.